Anteris Technologies has revealed its intention to launch an initial public offering (IPO) in the United States.
The company plans to utilize proceeds from the IPO to enhance the progression of its DurAVR transcatheter heart valve innovation. The offering includes 14.8 million shares of common stock, with an underwriters’ option to purchase an additional 2.22 million shares within 30 days. Anteris has submitted an application to list its shares on the Nasdaq Global Market under the ticker symbol AVR.
Funds raised through the IPO are earmarked for the continued advancement of the DurAVR transcatheter heart valve and the initiation of a pivotal global study focused on severe aortic stenosis treatment. Remaining financial resources will be directed towards working capital, corporate objectives, and the repayment of obligations related to convertible note facilities.
Exploring Anteris’ Heart Valve Technology
The DurAVR valve, a transcatheter heart valve innovation from Anteris, is engineered to address aortic stenosis. It distinguishes itself as one of the pioneering transcatheter aortic valve replacements crafted from a singular piece of bioengineered tissue. The biomimetic design aims to mimic the functionality of a healthy human aortic valve pocket.
The valve is constructed using Anteris’ exclusive anti-calcification tissue technology known as Adapt Tissue. Adapt has demonstrated clinical efficacy for more than a decade, serving over 55,000 patients globally.
Anteris claims their heart valve is delivered using the ComASUR Delivery System, which ensures a controlled deployment and precise placement with a system designed for balloon-expandable delivery. The company crafted this delivery method to enable optimal alignment with the heart’s native commissures, facilitating accurate valve positioning.